Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Oncoarendi Therapeutics LLC
Profile last edited on: 3/31/20      CAGE: 79GG3      UEI: KKZYNGZDKSC9

Business Identifier: Medicinal chemistry and preclinical biology,
Year Founded
2014
First Award
2016
Latest Award
2019
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

125 Devonshire Lane
Madison, CT 06443
   (609) 571-0306
   N/A
   www.oncoarendi.com
Location: Single
Congr. District: 02
County: New Haven

Public Profile

Oncoarendi Therapeutics LLC works in medicinal chemistry and preclinical biology. The company is focused on discovery & development of small molecules to treat patients with unmet medical needs. Researchers at OncoArendi study the therapeutic potential of chitinases and chitinase-like-proteins (CLPs) which provide multiple points for therapeutic intervention. OncoArendi currently has a platform of 3 distinct small molecule programs targeting chitinases and CLPs, with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need.

Extent of SBIR involvement

User Avatar
Phase I Awards
2
Phase II Awards
1
Conversion Rate
50.00%
Phase I Dollars
$462,200
Phase II Dollars
$1,505,420
Total Awarded
$1,967,620

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2019 1 NIH $237,200
Project Title: Potent Oral Chitotriosidase-1 Inhibitors as a Novel Therapy for Sarcoidosis
2018 2 NIH $1,730,420
Project Title: Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma

Key People / Management

  Pawel Dobrzanski

  Adam Golebiowski

  Reynold Alexander Panettieri

  Stanislaw Pikul

Company News

There are no news available.